KLOW Blend 80mg
An 80mg lyophilised four peptide blend for tissue repair and inflammation research. The combination has not been evaluated in published studies.
Search peptide names, research topics, guides and the latest news in one place.
120 results across the site
An 80mg lyophilised four peptide blend for tissue repair and inflammation research. The combination has not been evaluated in published studies.
A 50mg lyophilised synthetic peptide acting on GIP and glucagon like peptide 1 receptors. Supplied in a single vial for research, not as a licensed medicine.
A 10mg lyophilised synthetic amylin analogue studied in Phase 3 trials with semaglutide. Supplied in a single vial for research use only.
A 40mg lyophilised mitochondrial peptide studied mainly in mice and cell models for metabolism, insulin sensitivity and exercise capacity.
A 5mg small molecule NNMT inhibitor studied in cells and mice. Supplied for research, with no published human clinical trials.
A 10mg lyophilised synthetic cyclic heptapeptide activating melanocortin receptors, mainly MC4R. Supplied for research, not as a licensed medicine.
A 10mg lyophilised synthetic peptide corresponding to a region of thymosin beta 4. Studied in cell and animal models, with no human trials for this peptide.
Sterile water containing 0.9% benzyl alcohol, supplied in a 10ml vial for reconstituting lyophilised peptides and other compounds.
A lyophilised blend containing 10mg BPC-157 and 10mg TB-500. The combination itself has not been evaluated in published studies.
A 5mg lyophilised oxyntomodulin analogue acting on GLP-1 and glucagon receptors. Supplied for research, not as a licensed medicine.
A 5mg lyophilised 28 amino acid peptide studied in immune response regulation, particularly T cell function. Supplied for research, not as a licensed medicine.
An investigational weekly amylin receptor agonist with Phase 1/2 weight management findings and a Phase 3 programme spanning obesity, type 2 diabetes, sleep apnoea and knee osteoarthritis.
A review reports supplier sponsored sensory neuron experiments and a 20 participant split face, single blind topical study using a capsaicin discomfort endpoint.
A 2005 double blind split face moisturizer study and a 2023 21 participant randomized topical study reported exploratory cosmetic signals.
Research is cosmetic/cosmeceutical, including cell assays, patents, and formulation testing.
Located literature is chemical, computational, or supplier generated.
Human evidence located consists of small finished formulation studies, including a 24 participant 60 day study of acetyl hexapeptide 3 containing formulations.
Copper binding tripeptide research examines extracellular matrix signalling, fibroblast responses and topical formulation properties. The free peptide and copper complex have distinct identities.
Research largely concerns felypressin as the vasoconstrictor component of prilocaine with felypressin local anesthetic products, especially dental or cervical procedures.
Controlled ovarian stimulation studies evaluated ganirelix for prevention of premature LH surges.
A short thymosin beta 4 fragment listed in tissue biology research. Evidence for full length thymosin beta 4 should be distinguished from evidence for this four residue fragment.
It has phase II/III research in Cushing’s disease and acromegaly and distinct investigations in neuroendocrine tumors and perioperative pancreatic settings.
Vapreotide has historical research in variceal bleeding and other gastrointestinal/endocrine contexts; Antide research is separate and mainly preclinical.
Human research includes an exploratory 20 participant pulmonary hypertension study and COVID-19 respiratory failure trials.
The principal clinical research context was acute portal hypertension related oesophageal variceal bleeding.
Human research is concentrated in acute heart failure in Japan.
It was developed for treatment experienced HIV-1 infection; TORO studies found improved short term virologic response when added to optimized background therapy, with resistance associated gp41 substitutions documented.
Its primary clinical context is secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Large acute coronary syndrome and PCI research includes PURSUIT, in which eptifibatide reduced the 30 day composite of death or nonfatal MI but increased bleeding.
Small comparative Russian studies in anxiety/neurasthenia and phobic anxiety and somatoform disorders have been published, alongside animal, receptor, and gene expression work.
Direct evidence is older endocrine physiology and biochemical purification work, including 1982 pituitary cell and dog studies.
A GHRH analogue with randomised evidence of reduced visceral abdominal fat in adults with HIV associated lipodystrophy; defined finished products are authorised for that specific context, not general weight loss.
FDA labeling and registered studies support long acting subcutaneous histrelin implants for central precocious puberty and advanced prostate cancer contexts.
Research is biochemical, ex vivo, and rodent analgesia work.
Research includes pituitary cell, rat, and swine pharmacology and a registered human postoperative gastrointestinal function study.
Research mainly concerns prevention of postpartum haemorrhage.
Its established context is regulated adrenal reserve diagnostic stimulation.
Research includes peptide delivery and stability studies and established clinical pharmacology in central diabetes insipidus and selected hemostasis related conditions.
The strongest research is acute hereditary angioedema (HAE).
Clinical research includes acromegaly, carcinoid syndrome, and somatostatin receptor positive enteropancreatic neuroendocrine tumors.
It was developed as an investigational anticancer agent, principally in glioblastoma.
Research concerns GH stimulation testing and historical pediatric growth failure treatment.
Human evidence is very small and early: a three participant phase I pilot reported pigmentation and adverse effects, and a 20 participant erectile dysfunction study reported responses with frequent nausea/yawning.
The authorized clinical context is gallium 68 radiolabelling for PET imaging of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.
It has extensive human diabetes research as adjunct to insulin in type 1 and type 2 diabetes, with gastrointestinal adverse effects and clinically important hypoglycemia risk in the treatment setting.
Research includes cell and animal injury models and early human studies.
The strongest human context is diagnostic stimulation of pancreatic secretion and gastrin release.
Clinical research principally concerns hepatorenal syndrome with rapidly declining kidney function in advanced cirrhosis and related portal/hemodynamic contexts.
It was developed as a non opioid analgesic with clinical trials in severe chronic pain.
The best known human pharmacology study assessed DAC CJC-1295 in healthy adults.
It is primarily a native peptide research tool and physiologic reference.
Extensive human research in type 2 diabetes includes randomized studies and extensions of defined drug products.
It has phase III human research in type 2 diabetes, including add on studies with basal insulin and metformin.
Human research spans pituitary gonadal axis suppression, central precocious puberty, fertility protocols, and oncology.
A PTH(1–34) analogue with strong randomised evidence for reduced vertebral and nonvertebral fractures in specified high risk osteoporosis populations; authorisation applies to defined finished products, not a generic catalogue material.
Research spans animal reproductive biology, veterinary applications, and limited human investigation.
It is a mechanistic research reagent for endocrine regulation, gastrointestinal secretion/motility, metabolism, and receptor biology.
Research predominantly examines short term GH and pituitary responses.
It has extensive clinical research in acromegaly, secretory syndromes of certain neuroendocrine tumors, and gastroenteropancreatic neuroendocrine tumour research.
Human research uses sincalide as a controlled physiologic/diagnostic stimulus, including cholescintigraphy measurement standardization.
Human research and historical clinical use include endocrine stimulation testing, reproductive endocrinology, and pulsatile treatment of selected hypothalamic GnRH deficiency states.
It has extensive clinical and regulatory history in advanced prostate cancer and, depending on formulation and jurisdiction, endometriosis, fibroids, and central precocious puberty.
It is a clinical pharmacology and hormone dependent disease research agent.
The clearest documented context is veterinary reproductive endocrine research and controlled release implants, with limited human endocrine research.
Historical human research spans IVF protocols, endometriosis, hormone sensitive oncology, and pediatric endocrinology.
Human research has largely examined acute endocrine pharmacology, GH stimulation/testing, pharmacokinetics, and appetite biology.
Research is mainly experimental endocrine pharmacology, receptor biology, pharmacokinetics, and preclinical tissue protection work.
A guanylate cyclase C agonist with a defined GC-C/cGMP mechanism and randomised trial evidence in specified constipation related disorders; authorised uses depend on the finished product, population and jurisdiction.
The main human research context is celiac disease.
Research is dominated by animal and laboratory soft tissue, gastrointestinal, tendon, ligament, and muscle injury models.
A mitochondria targeting tetrapeptide with accelerated FDA approval for a defined Barth syndrome strength endpoint; broader mitochondrial myopathy and heart failure programmes remain investigational or have not met key endpoints.
Research comprises recombinant channel assays, neuronal studies, and mouse behavioral/neurogenesis experiments.
An investigational erythropoietin derived peptide with small early phase studies in sarcoidosis associated small fiber neuropathy, diabetic macular oedema and metabolic contexts; no authorised indication has been identified.
Research concerns opioid physiology, pain, stress, receptor pharmacology, analytical standards, animal models, and modified analogues/prodrugs.
An investigational human cathelicidin studied in topical venous leg ulcer trials and exploratory biomarker work; its broad antimicrobial, immune, regenerative and oncology research remains largely preclinical.
A parathyroid hormone related peptide analogue with Phase 3 osteoporosis evidence for fewer new vertebral and nonvertebral fractures and increased bone mineral density in postmenopausal women.
Evidence is principally preclinical pharmacology and rodent analgesia.
Research includes cell systems, spheroids, nanoparticles, imaging constructs, animal cancer models, and early human studies of related development compounds.
Research spans endometriosis, central precocious puberty, assisted reproduction, fibroids, and other pituitary gonadal axis contexts.
Evidence is largely rodent, isolated adipose tissue, and mechanistic research concerning lipid metabolism.
Osteogenic growth peptide research concerns bone, osteoblast, fracture healing, and hematopoietic models.
It is an experimental antigen used to induce or study experimental autoimmune encephalomyelitis in susceptible rodents.
Clinical research is primarily in type 2 diabetes.
It is principally a biochemical and preclinical research model.
Research concerns opioid signaling, pain and stress biology, neuroinflammation, addiction related processes, and inflammatory/cardiovascular models.
Research examines pain, stress/reward, neuroendocrine signaling, and associations with neurological/psychiatric conditions.
Evidence is predominantly cell, animal, and in silico research.
Research focuses on neuroprotection, stroke recovery, neurotrophin related signaling, and brain network effects.
The unacylated item mainly appears as a research intermediate, comparator, or building block in GLP-1 analogue design.
Human use is mainly measurement for diabetes classification, endogenous insulin assessment, and beta cell function trials.
An investigational triple hormone receptor agonist in Phase 3 trials spanning obesity, type 2 diabetes and obesity related conditions including sleep apnoea and knee osteoarthritis.
A GLP-1 receptor agonist supported by major randomised programmes in type 2 diabetes, chronic weight management and cardiovascular outcomes; authorisation depends on the named finished product, formulation, dose and indication.
A self assembling peptide studied in professional topical dental formulations for early, non cavitated caries; randomised evidence concerns lesion size and caries inactivation outcomes, not established cavities or generic peptide material.
An investigational small molecule injection studied in early Phase II/IIa programmes for localized abdominal subcutaneous fat and cellulite; it is not an authorised medicine and other development areas remain exploratory.
Nicotinamide adenine dinucleotide is a cellular coenzyme studied in redox reactions, energy metabolism and signalling. It is a small molecule cofactor rather than a peptide.
Copper peptide evidence is mainly mechanistic, cell, animal, topical and cosmetic, and review level.
China's research investment, biotechnology sector and clinical research infrastructure.
Ageing biology, peptide mechanisms and how to interpret longevity research.
Clinical trials, study design, endpoints and evidence levels.
Certificates of analysis, HPLC purity, molecular identity and batch documentation.
Supplier, batch, analytical test and documentation traceability.
Peptide identity, UK research enquiries, Retatrutide and common questions.
Our UK and Switzerland based team and manufacturer relationships in China.
Contact the team about research materials, documents and quotations.
Explore incretin, amylin and metabolic peptide research, including Retatrutide, Semaglutide and native signalling peptides. Records explain molecule identity, study context and available evidence.
Explore neuropeptide signalling, receptor pharmacology and experimental neuroscience. This collection brings together endogenous peptides and investigational compounds with distinct evidence profiles.
Explore peptides studied in pituitary and reproductive endocrine signalling. Records cover hormone analogues, receptor antagonists and their documented research contexts.
Explore growth hormone releasing peptides and endocrine research tools, including Sermorelin, Tesamorelin and CJC-1295 variants. Each record distinguishes the named material from related analogues.
Explore peptides used in skin, cosmetic formulation and dental materials research. Evidence varies between isolated molecules and finished formulations, so each record identifies the relevant study context.
Explore peptides studied in vascular signalling, cardiovascular physiology and haemodynamic research. Read the evidence context and molecular identity for each record.
Explore gastrointestinal peptide biology, secretion and receptor signalling. Records include native peptides, analogues and defined clinical reference molecules.
Explore peptides studied in cellular responses, mitochondrial biology and tissue models, including Elamipretide, LL-37 and Thymosin Beta-4. Each record explains the level and scope of the evidence.
Explore peptide research in bone turnover, osteoblast biology and mineral regulation. Records distinguish evidence for defined clinical products from the research materials listed in the catalogue.
Explore specialist peptide and cofactor research spanning imaging, oncology models and translational biology. Each record provides an entry point to molecular identity and supporting research context.
Three new peptide studies: AI designed lipopeptides, a frog derived peptide against resistant Acinetobacter, and a more stable teriparatide.
Five developments in peptide research, from oral therapies and phase 3 trials to cancer delivery and peptide chemistry. Updated 15 October 2026.
A 7 October Cell Metabolism report describes a multicentre phase 2 study of investigational UBT251, which targets GLP-1, GIP and glucagon receptors.
Researchers at the Chinese Academy of Sciences reported a Bac7-HC1 peptide conjugate that outperformed other tested combinations in laboratory and mouse infection models.
PPIKB brings together measured peptide binding data and experimentally resolved protein peptide structures for researchers working on peptide discovery and modelling.
A short guide to reading a research record, following cited sources and using this weekly news feature to find newly published peptide and China biotech research.